Inotuzumab Ozogamicin in the Treatment of MRD+ After HSCT of ALL

Clinical trial NCT05940961 · RECRUITING

Trial details

NCT number: NCT05940961
Sponsor: Sheng-Li Xue, MD
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

ALL MRD-positive Hematopoietic Stem Cell Transplantation

Start date: 2022-08-01
Primary completion: 2026-08-01
Enrollment: 42

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.